Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google
bearish
PegBio
Watchlist
PegBio (派格生物) IPO: Thoughts on Valuation
Equity Capital Markets
310 Views
11 Feb 2025 07:30
China's PegBio seeks to raise $150 million through Hong Kong listing. In this note, we provide an valuation framework for its key product PB-119.
What is covered in the Full Insight:
Introduction to PegBio IPO
Valuation of PB-119 for T2DM
Market Dynamics and Assumptions
SOTP Valuation of PegBio
Competitor and Patent Analysis
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 2-minute read)
Related Insights
More »
Loading
Trending Collections
More »
Index Rebalance
Equity Bottom-Up
Equity Derivatives
Technical Analysis
Unpaywalled Insights
Event-Driven
Philippines
Asia Event-Driven
India
South Korea
Trending Insights
More »
Errors in Local Street's Projections for the KOSPI 200 Rebalancing
Hang Seng Indexes: ADR Depositary Holding Changes; Round-Trip Trade Is US$5.1bn; NetEase Outperforms
KOSPI200 Index Rebalance Preview: 7 Changes a Side for June
CSI300 Index Rebalance Preview: 8 Changes a Side in June; US$4.5bn Trade
Quiddity Leaderboard ChiNext & ChiNext 50 Jun25: Last-Minute Methodology Changes; Final Expectations
Top Unpaywalled Insights
More »
The Rise of Quant Investing in Crypto w/ Truvius CEO Connor Farley | The New Barbarians #007
New Research: Unlocking Quantitative Alpha in Cryptocurrency Markets
The Evolution of Portfolio Management: Bridging Traditional Models and Machine Learning
Fractured Markets: Economic Consequences of the 2025 Tariffs
Unmasking ‘Fake Sales’: A Hidden Challenge In Indonesia’s E-Commerce Market
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
PegBio 派格生物 Pre-IPO: R&D Deceleration
30 Apr 2025
PegBio 派格生物 IPO: PHIP Updates Don’t Look Good
04 Mar 2025
PegBio (派格生物) IPO: Thoughts on Valuation
11 Feb 2025
PegBio 派格生物 IPO: A (Supposedly) Straightforward GLP-1 Challenger Story
05 Feb 2025
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.2
x